In a new study published in Nature, scientists have successfully developed genetically modified mosquitoes in Tanzania that block the transmission of malaria. The team includes researchers from the ...

A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites ...

NEW YORK (AP) — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs. Trump vilifies Kennedy ...

LONDON, Nov 12 (Reuters) - A new antimalarial drug developed by Novartis (NOVN.S), opens new tab is as effective as existing treatments and could help tackle rising drug resistance, the company said ...

GOP plans to replace Obamacare have failed. Here’s what lawmakers propose now. Virginia Giuffre's memoir reveals intimate details about her family life, children 11-year-old killed in road rage ...

Every cell of the deadly Plasmodium falciparum parasite, the organism that causes malaria, contains a tiny compartment full of microscopic iron crystals. As long as the parasite is alive, the crystals ...

Tawanda Zininga receives funding from the National Research Foundation and the Medical Research Council, who have no role in the project and its outcomes. Malaria remains one of the world’s most ...

Scientists from Drexel University’s College of Medicine and Columbia University’s Irving Medical Center have uncovered a crucial structural feature of a key malaria drug target, known as PfATP4, and ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives each year worldwide with limited efficacy in currently available treatments ...

Using millions of microscope images magnified up to 130,000 times, researchers from Radboud university medical center and Toronto have unraveled the structure of two key proteins in the malaria ...

A new malaria vaccine showed encouraging results in a phase 1 study conducted in Bamako, Mali, West Africa, a region where malaria remains a year-round threat to public health. Published in NEJM ...